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proportional Hazards models, including the following candidate covariables: age, sex,
diabetes, hypertension, hypercholesterolemia, current smoking, prior PCI, prior CABG,
previous MI, baseline creatinin clearance, baseline Hb, heart rate and systolic blood
pressure, peak CK-MB release and multivessel disease.
Results: Of 1602 patients with STEMI, 147 patients (9.3 %) developed a Hb decrease
> 4 g/dL. Of these, no bleeding focus could be established in 54 patients (3.4 %).
Patients with a Hb decrease ≥ 4 g/dL had a HR 1.61 (95 % CI 0.84 – 3.09, p 0.15) for
one year mortality if blood loss was observed, and a HR 3.18 (95% CI 1.49 – 6.76, p
= 0.003) if no blood loss was observed.
Conclusion: A periprocedural hemoglobin decrease irrespective of observed bleeding
represents a strong independent predictor for one year mortality. Compared with
patients who suffered observed blood loss, patients without observed blood loss had a
higher risk for one year mortality.
TCT-342
Accuracy of Acef, Euroscore and Syntax Score in Risk Stratification of Elderly
(≥70years) Patients Undergoing Primary Angioplasty
Flavia Ballocca1, Chiara Resmini1, Marco Di Cuia1, Sara Sturnia1, Fabrizio
D’Ascenzo1, Mario Bollati1, Claudio Moretti1, Filippo Sciuto1, Pier Luigi Omedè1,
Giuseppe Biondi Zoccai2, Imad Sheiban1, Fiorenzo Gaita1
1Ospedale S.Giovanni Battista Torino, Torino, Italy; 2Division of Cardiology
University of Modena and Reggio Emilia, Modena, Italy
Background: With increasing life expectancy the management of acute myocardial
infarction (AMI) in patients of an older age is of growing importance. However, data
are limited regarding risk stratification of ST-segment elevation myocardial infarction
(STEMI) in elderly people (≥70years). We thus performed a retrospective study to
compare the accuracy of three risk scores - ACEF, EuroSCORE and SYNTAX Score
- in subjects <70 and ≥70 years with STEMI.
Methods: We included 100 patients undergoing primay PCI at our centre from July
2002 to December 2005.We compared the accuracy in predicting MACE of the three
scores both in patients ≥70years and <70years using ROC curves and matching Areas
Under Curves (AUC).
Results: We included a total of 100 patients, 36 ≥70years and 64 <70years. The
percentages of male subjects (72.22% vs 93.75%, p=0.0029) and previous AMI (0%
vs 11.11%, p=0.0097) were higher in the <70 group, while in-stent restenosis (5.55%
vs 0%, p=0.0267) was more frequent in older patients. In patients ≥70years the best
predictor for MACE is SYNTAX Score (AUC 0.628, 95%CI 0.452- 0.783), followed
by ACEF (AUC 0.560, 95%CI 0.385-0.725) and EuroSCORE (AUC 0.536, 95%CI
0.362-0.703), but they do not differ significantly (ACEF vs EuroSCORE p=0.784,
ACEF vs SYNTAX Score p=0.616, EuroSCORE vs SYNTAX Score p=0.428). In
patients <70years better accuracy is shown by SYNTAX Score (AUC 0.613, 95%CI
0.483-0.732), than EuroSCORE (AUC 0.591, 95%CI 0.461-0.713) and ACEF (AUC
0.560, 95%CI 0.430-0.683), without a statistically significant difference (ACEF vs
EuroSCORE p=0.567, ACEF vs SYNTAX Score p=0.541, EuroSCORE vs SYNTAX
Score p=0.800).
Conclusion: All the assessed scores (ACEF, EuroSCORE and SYNTAX Score) have
a good accuracy in risk stratification of patients with STEMI undergoing primary PCI.
The greatest results in predicting MACE in both groups (≥70years and <70years) are
shown by SYNTAX Score; consequently SYNTAX Score might be proposed as a
scoring system to be used in both youger and older patients in the emergency setting.
TCT-343
In-Hospital Mortality of Patients Undergoing Primary Percutaneous Coronary
Intervention: Validation of the EuroHeart STEMI PCI Score
Ana Belen Cid Alvarez, Ramiro Trillo Nouche, Melisa Santas Alvarez, Diego Lopez
Otero, Raimundo Ocaranza Sanchez, Pablo Souto Castro, Rosa Agra Bermejo,
Francisco Gude Sampedro, Jose Ramon Gonzalez Juanatey
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela,
Spain
Background: A new scoring system, the EuroHeart score (EHs), was developed
recently in patients included in the PCI registry of the Euro Heart Survey. We assessed
the validity of this risk score in a contemporary cohort of patients admitted to our
hospital with ST elevation myocardial infarction (STEMI) who were undergoing
primary percutaneous coronary intervention (PPCI).
Methods: The study included 310 consecutive patients undergoing PPCI between
January 2009 and December 2010.The validity of the EHs was evaluated by assessing
its calibration using the Hosmer-Lemeshow test and its discriminatory capacity was
evaluated using the area under the ROC curve.
Results: The median patient age was 66 years, 73% were men and 26.5% had diabetes.
Percutaneous access was via the radial approach in 72% of the patients. The culprit
artery was the left anterior descending in 42.7% of the patients,31% had three-vessel
disease and a stent was implanted in 90% of the patients. The median EHs STEMI PCI
was 16[11–21]. We divided the patients into tertiles: EHs(1)≤14; EHs(2) >14 and ≤18;
EHs(3) >18. In-hospital mortality was 10.6%: 1% in EHs (1), 2% in EHs (2), and 3.7%
in EHs (3) (P<0.05). The EHs levels were an independent determinant of in-hospital
mortality in a multivariate analysis (HR IC95%: 1.164 (1.115–1.214), P<0.05). The
calibration of the EHs STEMI PCI was good (Hosmer-Lemeshow, P>0.5), and its
discriminatory capacity was excellent, with an area under the ROC curve of 0.91 (0.86–
0.97)
Conclusion: The EHs STEMI PCI for predicting in-hospital mortality was validated
in our cohort of patients. The EHs is easy to implement in clinical practice and is very
useful for the stratification of this group of patients.
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Background: Patients with AMI treated with PCI require long-term thienopyridine
therapy, yet the incidence of post-discharge bleeding and its association with
thienopyridine discontinuation in real-world practice is unknown.
Methods: TRANSLATE-ACS is an ongoing registry of AMI patients treated with PCI
and thienopyridine therapy. We examined the incidence of patient-reported “severe,
unexplained bruising or bleeding” by 6 weeks post-discharge, and bleeding-associated
thienopyridine cessation and rehospitalization (verified by billed diagnosis codes).
Results: Among 2177 AMI patients (53% STEMI) treated with PCI and discharged
on a thienopyridine, 322 (15%) reported any bleeding within 6 weeks post-discharge.
Patients enrolled to date who reported bleeding were younger (median 58 vs. 60 years,
p=0.04) and more likely to be female (40 vs. 26%, p<0.0001) than those without
bleeding. Between groups, there were no differences in MI type (STEMI vs. NSTEMI)
and in-hospital bleeding rates. Nuisance bleeding, such as severe bruising and nose
bleeds, were the most frequent bleeding complaints (Table). However, by 6 weeks post-
discharge, only 12 (3.7%) of 322 patients reporting bleeding required hospitalization
for bleeding and only 1 of these hospitalized patients stopped thienopyridine therapy
(due to thrombocytopenia). Among non-rehospitalized patients who reported bleeding,
4 patients (1.2%) had stopped thienopyridine therapy due to bleeding by 6 weeks.
Conclusion: While nuisance bleeding or bruising is a frequent complaint during the
early post-discharge time period among PCI-treated AMI patients, bleeding is only
rarely associated with antiplatelet therapy discontinuation or rehospitalization.
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